Glioblastoma (GBM) is an extremely aggressive tumor of the central nervous system, with a
prognosis of 12–15 months and just 3–5% of survival over 5 years. This is mainly because …

The transcription factor NF-κB is commonly known to drive inflammation and cancer
progression, but is also a crucial regulator of a broad range of cellular processes within the …

Background Management of triple-negative breast cancer (TNBC) is still challenging
because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin …

This systematic review assesses current molecular targeted therapies for glioblastoma
multiforme (GBM), a challenging condition with limited treatment options. Using PRISMA …

Cell-specific aptamers are a promising emerging player in the field of disease therapy. This
paper reviews the multidimensional research progress made in terms of their classification …

Background Triple-negative breast cancer (TNBC) is a uniquely aggressive cancer with high
rates of relapse due to resistance to chemotherapy. TNBC expresses higher levels of …

Polymeric nanoparticles (PNPs) may efficiently deliver in vivo therapeutics to tumors when
conjugated to specific targeting agents. Gint4. T aptamer specifically recognizes platelet …

Aptamers are nucleic acids referred to as chemical antibodies as they bind to their specific
targets with high affinity and selectivity. They are selected via an iterative process known as …

Targeted DNA nanoparticles have been identified as one of the most promising nanocarriers
in anti-glioma drug delivery. We established a multifunctional nanosystem for targeted …

Aptamers, also known as chemical antibodies, are single-stranded nucleic acid
oligonucleotides which bind to their targets with high specificity and affinity. They are …